An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

Starting this spring, the Respiratory Syncytial Virus (RSV) vaccine will be available to adults aged 60 years and older residing in congregate living facilities, such as long-term care homes and ...

With the RSV season officially underway in South Africa, experts are urging healthcare providers to prepare for an influx of ...

The rollout of a vaccine for respiratory syncytial virus (RSV) has slashed hospital admissions by 30% among older people, ...

Early data suggests that the respiratory syncytial virus (RSV) vaccination programme is significantly reducing hospital admissions among ...

A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.

Abrysvo, which is now the first maternal RSV vaccine to be prequalified by the organisation, aims to prevent RSV-associated ...

MANILA, Philippines — Respiratory Syncytial Virus (RSV) is a common, contagious virus affecting the lungs and breathing passages. It usually causes mild, cold-like symptoms that are often ...

Provincial health officer Dr. Bonnie Henry said B.C.'s COVID-19 hospitalizations have hit the lowest level since 2020, with ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...